The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Matching-adjusted indirect comparison of Isa-Kd versus Dara-Rd in relapsed multiple myeloma
Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, shares the findings from a matching-adjusted indirect comparison (MAIC) of isatuximab plus carfilzomib and dexamethasone (Isa-Kd) versus daratumumab plus lenalidomide and dexamethasone (Dara-Rd) in patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant/advisor: Janssen, BMS, Pfizer, Karyopharm, Sanofi, Takeda, Abbvie, Genentech
Speakers bureau: Janssen, BMS, Sanofi, Adaptive Biotechnologies
